TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02023970

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients receiving animal-derived bioprosthetic heart valves.

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients receiving animal-derived bioprosthetic heart valves.

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients receiving animal-derived bioprosthetic heart valves.

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (1)

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (2)

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography (3)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (1)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (2)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample (3)
Study: NCT01167725

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT03300349

Intervention type: OTHER
Intervention: Fulfillment of a preventive programme
Description: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder

Intervention type: OTHER
Intervention: Fulfillment of a preventive programme
Description: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder

Intervention type: OTHER
Intervention: No fulfillment of a preventive programme
Description: No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
Study: NCT01167725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given intraperitoneally
Study: NCT03300349

Intervention type: OTHER
Intervention: No fulfillment of a preventive programme
Description: No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
Study: NCT02846181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SK-1405
Study: NCT01167725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo cytoreductive surgery
Study: NCT03621254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [LO-LONG]
Description: Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [HI-SHORT
Description: One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
Study: NCT04068831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg talazoparib daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg talazoparib daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg avelumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 800 mg avelumab every 2 weeks
Study: NCT03624465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Magnetic Surgical System
Description: Device for use as a surgical tool.
Study: NCT02223923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Study: NCT04339192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Tricuspid Surgery
Description: minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
Study: NCT05598216

Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention, Serum LDL cholesterol calculation
Description: The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)

Intervention type: DIAGNOSTIC_TEST
Intervention: no intervention, Serum LDL cholesterol calculation
Description: The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
Study: NCT00556933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - single dose
Description: A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - single dose
Description: A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
Study: NCT04406142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISUAL
Description: thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
Study: NCT02137239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Study: NCT01880723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: nebulized 3mL normal saline) using a Power Neb2 nebulizer
Study: NCT04486391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg administered via intravenous (IV) infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvage Chemotherapy
Description: Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
Study: NCT02137239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil(MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus(EVL)
Study: NCT03129828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and Bortezomib + R-CHOP
Description: A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
Study: NCT03313999

Intervention type: DEVICE
Group type: OTHER
Intervention: Lymphedema Indentometer
Description: The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
Study: NCT04505410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A plant based high fiber diet that mimics fasting (FMD) plus advanced therapy
Description: Patients will do two 5-day cycles of a fasting mimicking diet. They will start the first diet cycle 1 week after initiating a new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advanced therapy only without dietary intervention
Description: Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
Study: NCT02137239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus(TAC)
Study: NCT00760630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR/CFR and IVUS
Description: All patients with clinical indication for cardiac cath will have FFR and IVUS
Study: NCT03684707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hcl 500Mg 24Hr Sa Tab
Description: Glucophage 500 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch tablet
Description: starch tablets
Study: NCT02505750

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal EBRT
Description: External Beam Radiation Therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D conformal EBRT
Description: External Beam Radiation Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact X-ray brachytherapy 50 kV
Study: NCT04287868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDS0101
Description: PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDS0101
Description: PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
Study: NCT04046549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit.
Study: NCT03493542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V501
Description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
Study: NCT02505750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT03091543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS 125
Description: 1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS 125
Description: 1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS 125
Description: 1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
Study: NCT01942538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: same session as defined with the real rTMS, but with a coil not delivering magnetic field.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: same session as defined with the real rTMS, but with a coil not delivering magnetic field.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: same session as defined with the real rTMS, but with a coil not delivering magnetic field.
Study: NCT02029521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral reduced l-glutathione
Description: The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
Study: NCT02592044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral venous cannulation
Description: The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: peripheral venous cannulation
Description: The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Description: The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
Study: NCT03091543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS 125
Description: 1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® HBS 125
Description: 1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg dose
Description: 1 capsule of 25 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg dose
Description: 1 capsule of 25 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg dose
Description: 1 capsule of 25 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg dose
Description: 1 capsule of 25 mg plus 1 capsule of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg dose
Description: 1 capsule of 25 mg plus 1 capsule of placebo
Study: NCT04320199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Protaetia brevitarsis seulensis powder group
Description: This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes placebo for 8 weeks